The 2017 International Classification of the Ehlers–Danlos Syndromes (EDS) proposes a revised classification that recognizes 13 subtypes, recognizing the vast genetic heterogeneity and phenotypic variability of EDS. The classification maintains a clinical classification with descriptive names for each subtype, while also providing a pathogenetic scheme to group subtypes based on shared causative proteins. For each subtype, clinical criteria are proposed to aid diagnosis, though molecular confirmation is essential for definitive diagnosis, except for the hypermobile type (hEDS). The hEDS diagnosis remains clinical due to the lack of a reliable genetic test, but specific criteria are provided to reduce heterogeneity and guide future research. The classification aims to serve as a new standard for diagnosis and provide a framework for future research.The 2017 International Classification of the Ehlers–Danlos Syndromes (EDS) proposes a revised classification that recognizes 13 subtypes, recognizing the vast genetic heterogeneity and phenotypic variability of EDS. The classification maintains a clinical classification with descriptive names for each subtype, while also providing a pathogenetic scheme to group subtypes based on shared causative proteins. For each subtype, clinical criteria are proposed to aid diagnosis, though molecular confirmation is essential for definitive diagnosis, except for the hypermobile type (hEDS). The hEDS diagnosis remains clinical due to the lack of a reliable genetic test, but specific criteria are provided to reduce heterogeneity and guide future research. The classification aims to serve as a new standard for diagnosis and provide a framework for future research.